Heart failure & cardiomyopathiesMeta-analysis

Absence of Fibrosis Influences Prognosis of Cardiac Resynchronization in Nonischemic Cardiomyopathy

JACC AdvPublished

  • systematic review and meta-analysis
  • observational studies
  • cardiac magnetic resonance before cardiac resynchronization therapy (CRT) implantation

Authors' conclusion

In NICM patients undergoing CRT, the absence of LGE is strongly associated with greater echocardiographic response and very low arrhythmic risk. In this subgroup the incremental benefit of CRT with defibrillator over CRT-P may be limited.

Study context

Population
Patients with nonischemic cardiomyopathy (NICM) who underwent cardiac magnetic resonance before CRT implantationTen studies included · CRT response (9 studies) 831 · arrhythmic risk (6 studies) 745
Comparison
patients without late gadolinium enhancement (LGE) vs patients with LGE

Pooled result

Echocardiographic CRT response

Odds ratio

3.52

95% CI 2.54–4.88

P < 0.001

By group

patients without LGE vs patients with LGE
OR 3.52 (95% CI 2.54–4.88); P < 0.001

As reported in the abstract

Further pooled results

OutcomeOR (95% CI)P value
Ventricular arrhythmia (sustained ventricular tachycardia, appropriate implantable cardioverter-defibrillator therapy, resuscitated cardiac arrest, sudden death) · absence of LGE associated with much lower arrhythmic risk0.06 (0.02–0.15)P < 0.001

Cumulative incidence

Outcomepatients without LGEpatients with LGEEstimateP value
Ventricular arrhythmia (sustained ventricular tachycardia, appropriate implantable cardioverter-defibrillator therapy, resuscitated cardiac arrest, sudden death) · significantly lower in LGE cases than LGE+ ones0.8%21.1%P < 0.001
  • Ventricular arrhythmia (sustained ventricular tachycardia, appropriate implantable cardioverter-defibrillator therapy, resuscitated cardiac arrest, sudden death): abstract labels the groups 'LGE cases' vs 'LGE+ ones' for this result

Original publication

Absence of Fibrosis Influences Prognosis of Cardiac Resynchronization in Nonischemic Cardiomyopathy. JACC Adv. Published 1 October 2026. doi:10.1016/j.jacadv.2026.103295

Summarised from the published abstract; every number is checked against it